First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Terumo: the story is balanced — Cardiac & Vascular segment growth rates, particularly drug-eluting stent market share in US and Europe against Abbott's…
★ Analysts see FY2027 revenue reaching $1.23T — +8.1% growth in a single year.
What Moves the Stock
1Cardiac & Vascular segment growth rates, particularly drug-eluting stent market share in US and Europe against Abbott's Xience and Boston Scientific's Synergy platforms
2Japanese yen exchange rate fluctuations (60% of revenue is international, primarily USD and EUR denominated, creating translation exposure)
3Hospital capital equipment spending trends in developed markets, driven by elective procedure volumes and healthcare system budgets
4Regulatory approvals and clinical trial results for pipeline products, especially next-generation cardiovascular devices and neurovascular technologies
5China market penetration and volume-based procurement (VBP) pricing impact on interventional cardiology products
6Cardiac & Vascular Company (~45-50% of revenue): Interventional cardiology devices including drug-eluting stents, PTCA balloons, catheters, vascular closure devices, and neurovascular products
7General Hospital Company (~30-35% of revenue): Infusion therapy systems, drug delivery devices, blood glucose monitoring systems, peritoneal dialysis products, and surgical equipment
8Blood & Cell Technologies Company (~15-20% of revenue): Blood collection systems, therapeutic apheresis equipment, cell processing technologies, and blood component separation systems
value - The stock's 30.8% decline over the past year, combined with reasonable valuation metrics (2.7x P/S…
Rising interest rates create moderate headwinds through multiple channels: (1) hospital capital equipment financing becomes more expensive…
Watch on earnings: Japanese yen exchange rate (USD/JPY and EUR/JPY) for translation impact on international revenue and margins, US hospital capital equipment spending trends and elective procedure volumes (proxy for cardiac intervention demand), China healthcare infrastructure investment and VBP program expansion timeline for cardiovascular devices.
One Sentence Summary:
Terumo: the story is balanced — cardiac & vascular segment growth rates, particularly drug-eluting stent market share in us and europe against abbott's xience and boston.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.